>> But I'm always learning new things, so one day I'm studying some rare orphan disease
that very few people have, another day I'm studying a new type of cancer,
osteoporosis, cardiovascular diseases.
I'm always learning about new disease areas, what the cutting edge of therapies are;
and also about what are the decisions that are broader level,
how healthcare is becoming increasingly expensive, how might we approach it.
And I learn a lot about how things work in other countries.
So with the US Affordable Care Act coming into play, how does it work in other countries
that have had some form of socialized medicine for a long time?
So it's interesting to get that perspective.
The pharmaceutical companies expect it will help them, because more people will have ability
to pay for drugs, so there will be more people able to take medications.
The health insurance industry is going to be allowed to offer policy,
so although people are worried that, I mean, it will hurt employers if they're required to,
it's going to really help a lot of industries.
And my say is I'm not sure why employers should have to fund health insurance.
It might be helpful to let it just be as a social, you know,
a function that people are able to select the policy they want, but that it's funded
at the government level, rather than the employer level.
The hardest part sometimes for me is understanding the business need.
So I like work with a lot of folks who have very tight deadlines, they have a drug that's coming
to market, they need information very quickly.
And I am still very much the researcher at heart, and so to try to go
from a research timeline, which can take years, to a business timeline,
which can be months, can be challenging.
And to be able to translate complex technological information in a manner
that people who are making business decisions can understand,
so that's an area that can sometimes be a challenge.